JP2013544239A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544239A5
JP2013544239A5 JP2013536694A JP2013536694A JP2013544239A5 JP 2013544239 A5 JP2013544239 A5 JP 2013544239A5 JP 2013536694 A JP2013536694 A JP 2013536694A JP 2013536694 A JP2013536694 A JP 2013536694A JP 2013544239 A5 JP2013544239 A5 JP 2013544239A5
Authority
JP
Japan
Prior art keywords
amino
pharmaceutical formulation
purin
cyclohexanol
furanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013536694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544239A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/057460 external-priority patent/WO2012061061A1/en
Publication of JP2013544239A publication Critical patent/JP2013544239A/ja
Publication of JP2013544239A5 publication Critical patent/JP2013544239A5/ja
Pending legal-status Critical Current

Links

JP2013536694A 2010-10-25 2011-10-24 置換されているジアミノプリンの薬学的製剤 Pending JP2013544239A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40629210P 2010-10-25 2010-10-25
US61/406,292 2010-10-25
US201161481378P 2011-05-02 2011-05-02
US61/481,378 2011-05-02
US201161528427P 2011-08-29 2011-08-29
US61/528,427 2011-08-29
US201161537963P 2011-09-22 2011-09-22
US61/537,963 2011-09-22
PCT/US2011/057460 WO2012061061A1 (en) 2010-10-25 2011-10-24 Pharmaceutical formulations of a substituted diaminopurine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016088076A Division JP2016155854A (ja) 2010-10-25 2016-04-26 置換されているジアミノプリンの薬学的製剤

Publications (2)

Publication Number Publication Date
JP2013544239A JP2013544239A (ja) 2013-12-12
JP2013544239A5 true JP2013544239A5 (cg-RX-API-DMAC7.html) 2014-12-04

Family

ID=44913416

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013536694A Pending JP2013544239A (ja) 2010-10-25 2011-10-24 置換されているジアミノプリンの薬学的製剤
JP2016088076A Pending JP2016155854A (ja) 2010-10-25 2016-04-26 置換されているジアミノプリンの薬学的製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016088076A Pending JP2016155854A (ja) 2010-10-25 2016-04-26 置換されているジアミノプリンの薬学的製剤

Country Status (7)

Country Link
US (2) US8603527B2 (cg-RX-API-DMAC7.html)
EP (1) EP2632439B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013544239A (cg-RX-API-DMAC7.html)
KR (1) KR20130142141A (cg-RX-API-DMAC7.html)
CN (1) CN103298454B (cg-RX-API-DMAC7.html)
AU (1) AU2011323807B2 (cg-RX-API-DMAC7.html)
WO (1) WO2012061061A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603527B2 (en) * 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
JP6910946B2 (ja) 2014-08-25 2021-07-28 アイミューン セラピューティクス,インコーポレイテッド タマゴのタンパク質製剤およびその製造方法
DK3204386T3 (da) 2014-10-06 2021-05-25 Signal Pharm Llc Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
US10576085B2 (en) 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MX379439B (es) * 2016-04-01 2025-03-10 Signal Pharm Llc Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1-metilciclohexano-1-carboxamida y métodos para utilizarlas.
CN106632339B (zh) * 2016-12-16 2018-11-27 温州医科大学 一种6-取代-9h-嘌呤类衍生物及其制备方法和应用
WO2018200534A1 (en) * 2017-04-24 2018-11-01 Samus Therapeutics, Inc. Hsp90 inhibitor oral formulations and related methods
EP3692041A1 (en) 2017-10-04 2020-08-12 Celgene Corporation Processes for the preparation of cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
MX2020003620A (es) 2017-10-04 2020-10-28 Celgene Corp Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida.
CN110921918B (zh) * 2019-12-18 2021-12-31 山东理工大学 氨基芳磺酸类废水的处理方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
NZ555909A (en) * 2004-12-13 2009-11-27 Mcneil Ppc Inc Compositions and methods for reducing the degradation of phenylephrine by oxygen
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2007062338A2 (en) 2005-11-18 2007-05-31 Astrazeneca Ab Solid formulations
NZ576347A (en) 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
DK2279731T3 (da) * 2008-04-23 2013-03-18 Farmasierra Mfg S L Forbedret farmaceutisk sammensætning, som indeholder ibuprofen og codein
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) * 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines

Similar Documents

Publication Publication Date Title
EP2730278A1 (en) Composition melt
JP2005194283A5 (cg-RX-API-DMAC7.html)
JP2017501140A5 (cg-RX-API-DMAC7.html)
JP2018065876A (ja) ニロチニブと選択された共結晶体を含有する多成分結晶系
JP2017528503A5 (cg-RX-API-DMAC7.html)
US20190315727A1 (en) Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
JP2017528506A5 (cg-RX-API-DMAC7.html)
KR102759845B1 (ko) 2-{4-[n-(5,6-디페닐피라진-2-일)-n-이소프로필아미노]부틸옥시}-n-(메틸술포닐)아세트아미드를 함유하는 의약 조성물
RU2010113965A (ru) Гамма-1-msh отдельно или в сочетании с пентагастрином в качестве терапевтического средства
JP2016505019A5 (cg-RX-API-DMAC7.html)
JP2017510624A5 (cg-RX-API-DMAC7.html)
RU2016123828A (ru) Комбинированная композиция для перорального введения, содержащая эзетимиб и розувастатин
RU2010114011A (ru) Терапевтическое применение пептида yglf и сочетания с kvlpvpq
TW201501730A (zh) 用於口服投藥之包含非晶型托伐普坦(Tolvaptan)的懸浮液
JP7166292B2 (ja) N-{4-[(6,7-ジメトキシキノリン-4-イル)オキシ]フェニル}-n’-(4-フルオロフェニル)シクロプロパン-1,1-ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法
JP2018521121A5 (cg-RX-API-DMAC7.html)
JP2024518685A5 (cg-RX-API-DMAC7.html)
FI4313058T3 (fi) Roginolisibia käsittävä koostumus ja annosteluohjelma syövän tai tulehdus- tai autoimmunisairauden hoitoon
JP2013526491A (ja) メチソシルデナフィル・クエン酸塩結晶型o及びその調製方法並びに応用
US20210308104A1 (en) Pharmaceutical composition comprising eltrombopag olamine
JP6839708B2 (ja) 8−[(3r)−3−アミノ−1−ピペリジニル]−7−(2−ブチン−1−イル)−3,7−ジヒドロ−3−メチル−1−[4−メチル−2−キナゾリニル)メチル]−1h−プリン−2,6−ジオンまたは薬学上許容できるその塩を含有する医薬組成物
US20170007602A1 (en) Pharmaceutical dosage forms
TW200927118A (en) Treatment of vasomotor symptoms
JP6130595B2 (ja) ピロロキノリンキノンリチウム塩の結晶体及び調製方法と応用
US20170224852A1 (en) Benzazepin-1-ol-derived pet ligands with high in vivo nmda specificity